2025年9月22日,A股创新型生物医药公司智翔金泰(股票代码:688443.SH)宣布与康哲药业(港股代码:00867.HK)附属公司西藏康哲,以及RXILIENT MEDICAL PTE.LTD.分别达成独家商业化合作协议。合作标的包括两款在研单克隆抗体产品:唯康度塔单抗注射液(GR2001)与斯乐韦米单抗注射液(GR1801)。根据协议,康哲药业获得GR2001与GR1801在中国大陆市场的...
Source Link2025年9月22日,A股创新型生物医药公司智翔金泰(股票代码:688443.SH)宣布与康哲药业(港股代码:00867.HK)附属公司西藏康哲,以及RXILIENT MEDICAL PTE.LTD.分别达成独家商业化合作协议。合作标的包括两款在研单克隆抗体产品:唯康度塔单抗注射液(GR2001)与斯乐韦米单抗注射液(GR1801)。根据协议,康哲药业获得GR2001与GR1801在中国大陆市场的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.